The second British Viral Hepatitis Group (BVHG) meeting of the 2011 series, ‘Delta Virus: a national outcomes framework – meeting NICE’s diagnosis challenge’, was given a high approval rating by delegates, speakers and sponsors.

The meeting, organised by GBCPR and held at the King’s Fund in central London on 18 April 2011, was made possible by funding from five pharmaceutical companies, Gilead Sciences, Bristol-Meyers Squibb, Janssen-Cilag, Roche Products and MSD.

GBCPR provide secretariat services to the BVHG, but is also responsible for sponsorship generation, organising a series of one day educational events aimed at clinicians and hepatology nurse specialists and ensuring that the Group’s views are considered by the Department of Health and the National Institute for Health and Clinical Excellence.

The first of this year’s BVHG programme of events was also hailed a success. The meeting covered New Drugs for Hepatitis C and was held at Wallacespace in central London at the end of January. Again funding for the educational event came from Bristol-Myers Squibb Pharmaceuticals, Gilead Sciences, Janssen-Cilag, Roche Products and MSD.

For further details of the 2011 BVHG programme of medical education programmes and sponsorship opportunities contact Geoffrey Bowden on 01273 622212